Nanostructural hybrid sensitizers for photodynamic therapy

Current Pharmaceutical Design

Volumn 18, Issue 18, 2012, Pages 2607-2621

  Kepczynski, Mariusz ^a   Dzieciuch, Monika ^a   Nowakowska, Maria ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antibacterial treatment; Liposomes; Photodynamic therapy; Poly(ethylene glycol); Polymeric photosensitizers; Porphyrins; Tumor cells

Indexed keywords

CHLORINE DERIVATIVE; DRUG CARRIER; HYPOCRELLIN B; LIPOSOME; MACROGOL; NANOMATERIAL; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PLATINUM DERIVATIVE; POLYMER; PORPHYRIN DERIVATIVE; PYROPHEOPHORBIDE ALPHA METHYL ESTER; REACTIVE OXYGEN METABOLITE; TEMOPORFIN; UNCLASSIFIED DRUG; VERTEPORPHIN;

ANIMAL CELL; APOPTOSIS; BLADDER CANCER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHILICITY; MICELLE; MOLECULAR WEIGHT; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; TUMOR CELL;

EID: 84862513708     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800492877     Document Type: Review

References (88)

1. Gray J, Fullarton G. The current role of photodynamic therapy in oesophageal dysplasia and cancer. Photodiagn Photodyn Ther 2007; 4: 151-9.
2. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic Therapy. J Natl Cancer Inst 1998; 90: 889-905.
3. Celli JP, Spring BQ, Rizvi I, et al. Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization. Chem Rev 2010; 110: 2795-2838.
4. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 2004; 1: 279-93.
5. Dai T, Huang Y-Y, Hamblin MR. Photodynamic therapy for localized infections-State of the art. Photodiagn Photodyn Ther 2009; 6: 170-188.
6. Kessel D, Dougherty TJ. Agents used in photodynamic therapy. Contemp Pharmacother 1999; 10: 19-24.
7. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH. Photosensitizers in clinical PDT. Photodiagn Photodyn Ther 2004; 1: 27-42.
8. O'Connor AE, Gallagher WM, Byrne AT. Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochem Photobiol 2009; 85: 1053-1074.
9. Bonnett R, Berenbaum MC. HpD - a study of its components and their properties. Adv Exp Med Biol 1983; 160: 241-50.
10. Peng Q, Warloe T, Berg K, Moan et al. 5-Aminolevulinic acidbased photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308.
11. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-40.
12. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-24.
13. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42: 547-57.
14. Houle JM, Strong HA. Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. Retina 2002; 22: 691-7.
15. Copper MP, Tan IB, Oppelaar H, Ruevekamp MC, Stewart FA. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in earlystage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2003; 129: 709-11.
16. Spikes JD. Chlorins as photosensitizers in biology and medicine. J Photochem Photobiol B 1990; 6, 259-74.
17. Hornung R, Fehr MK, Walt H, Wyss P, Berns MW, Tadir Y. PEGm- THPC-mediated Photodynamic Effects on Normal Rat Tissues. Photochem Photobiol 2000;72: 696-700.
18. Seidl J, Rauch J, Krieg RC, Appel S, Baumgartner R, Knuechel R. Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acidinduced protoporphyrin IX as sensitizer. Int J Cancer 2001; 92: 671-677.
19. Mlkvy, P, Messmann H, Regula J, et al. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5- aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. Neoplasma 1995; 42: 109-13.
20. Peng Q, Moan J, Ma LW, Nesland JM. Uptake, localization, and photodynamic effect of meso-tetra(hydroxypheny1)porphine and its corresponding chlorin in normal and tumor tissues of mice bearing mammary carcinoma. Cancer Res 1995; 55: 2620-6.
21. Braichotte D, Savary J-F, Glanzmann T, et al. In vivo pharmacokinetic studies of tetra(meta-hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths. Int J Cancer 1995; 63: 198-204.
22. Jocham D, Baumgartner R, Stepp H, Unsold E. Clinical experience with the integral photodynamic therapy of bladder carcinoma. J Photochem Photobiol B 1990; 6: 183-7.
23. Prinsze C, Penning LC, Dubbelmann TM, Van Steveninck J. Interaction of photodynamic treatment and either hyperthermia or ionizing radiation and of ionizing radiation and hyperthermia with re spect to cell killing of L929 fibroblasts, Chinese hamster ovary cells, and T24 human bladder carcinoma cells. Cancer Res 1992; 52: 117-20.
24. Ochsner M. Photodynamic therapy: the clinical perspective. Review on applications for control of diverse tumorous and nontumorous diseases. Drug Res 1997; 47: 1185-94.
25. Fisher AMR, Murphree AM, Gomer CJ. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995; 17: 2-31.
26. Nowakowska M, Nawalany K, Kepczynski M, Krawczyk Z. Novel Nanostructural Hybride Materials for Photodynamic Theraphy. Macromol Symp 2009; 279: 132-37.
27. Margalit R, Cohen S. Studies of hematoporphyrin and hematoporphyrin derivative equilibria in heterogeneous systems. Porphyrinliposome binding and porphyrin aqueous dimerization. Biochim Biophys Acta 1983; 736: 163-170.
28. Pasternack RF, Huber PR, Boyd P, et al. Aggregation of mesosubstituted water-soluble porphyrins. J Am Chem Soc 1972; 94: 4511-7.
29. Hoebeke M. The importance of liposomes as models and tools in the understanding of photosensitization mechanisms. J Photochem Photobiol B 1995; 28: 189-96.
30. Ehrenberg B. Assessment of the partitioning of probes to membranes by spectroscopic titration. J Photochem Photobiol B 1992; 14: 383-386.
31. Kepczynski M, Nawalany K, Kumorek M, Kobierska A, Jachimska B, Nowakowska M. Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem Phys Lipids 2008; 155: 7-15.
32. Gross E, Ehrenberg B. The partition and distribution of porphyrins in liposomal membranes. A spectroscopic study. Biochim Biophys Acta 1989; 983: 118-22.
33. Kepczynski M, Pandian RP, Smith KM, Ehrenberg B. Do Liposome-binding Constants of Porphyrins Correlate with Their Measured and Predicted Partitioning Between Octanol and Water? Photochem Photobiol 2002; 76: 127-34.
34. Paszko E, Ehrhardt C, Senge MO, Kelleherd DP, Reynolds JV. Nanodrug applications in photodynamic therapy. Photodiagn Photodyn Ther 2011; 8: 14-29.
35. Copley L, van der Watt P, Wirtz KW, Parker MI, Leaner VD. PhotolonTM, a chlorin e6 derivative, triggers ROS production and light-dependent cell death via necrosis. Int J Biochem Cell Biol 2008; 40: 227-35.
36. Kuśmierz D, Latocha M, Zielińska A, Nawrocka-Musiał D, Sliupkas-Dyrda E. The Expression of the Melanogenesis Pathway Genes TYR, TYRP-1, and TYRP-2 and the Synthesis of Melanin in SH-4 Melanoma Cells After Photodynamic Therapy with Photolon. Adv Clin Exp Med 2009; 18: 449-59.
37. Lee LS, Ping Thong PS, Olivo M, et al. Chlorin e6- polyvinylpyrrolidone mediated photodynamic therapy - A potential bladder sparing option for high risk non-muscle invasive bladder cancer. Photodiagn Photodyn Ther 2010; 7: 213-20.
38. Li B, Moriyama EH, Li F, Jarvi MT, Allen C, Wilson BC. Diblock Copolymer Micelles Deliver Hydrophobic Protoporphyrin IX for Photodynamic Therapy. Photochem Photobiol 2007; 83: 1505-12.
39. Master AM, Rodriguez ME, Kenney ME, Oleinick NL, Sen Gupta A. Delivery of the Photosensitizer Pc 4 in PEG-PCL Micelles for In vitro PDT Studies. J Pharm Sci 2010; 99: 2386-98.
40. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an Emerging Class of Therapeutics. Annu Rev Med 2005; 56: 555-83.
41. Shieh YA, Yang SJ, Wei MF, Shieh MJ. Aptamer-Based Tumor- Targeted Drug Delivery for Photodynamic Therapy. Bioconjugate Chem 2010; 21: 1312-20.
42. Olea AF, Thomas JK. Fluorescence studies of the conformational changes of poly(methacrylic acid) with pH. Macromolecules 1989; 22: 1165-9.
43. Liu G, Guillet JE, Al-Takrity ETB, Jenkins AD, Walton DRM. Dimensions of polyelectrolytes using the spectroscopic ruler. 2. Conformational changes of poly(methacrylic acid) chains with variation in pH. Macromolecules 1991; 24: 68-74.
44. Kepczynski M, Karewicz A, Gornicki A, Nowakowska M. Interactions of Porphyrin Covalently Attached to Poly(methacrylic acid) with Liposomal Membranes. J Phys Chem B 2005; 109: 1289-94.
45. Zelikin AN, Breheney K, Robert R, Tjipto E, Wark K. Cytotoxicity and Internalization of Polymer Hydrogel Capsules by Mammalian Cells. Biomacromolecules 2010; 11: 2123-9.
46. Kepczynski M, Nawalany K, Jachimska B, Romek M, Nowakowska M. Pegylated tetraarylporphyrin entrapped in liposomal membranes. A possible novel drug-carrier system for photodynamic therapy. Colloids Surf B 2006; 49: 22-30.
47. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55: 217-50.
48. Westermann P, Glanzmann T, Andrejevic S, et al. Long Circulating Half-Life And High Tumor Selectivity Of The Photosensitizer Meta-Tetrahydroxyphenylchlorin Conjugated To Polyethylene Glycol In Nude Mice Grafted With A Human Colon Carcinoma. Int J Cancer 1998; 76: 842-50.
49. Hornung R, Fehr MK, Monti-Frayne J, et al. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model. Photochem Photobiol 1999; 70: 624-9.
50. Grahn MF, Giger A, McGuinness A, et al. mTHPC Polymer Conjugates: The In vivo Photodynamic Activity of Four Candidate Compounds. Lasers Med Sci 1999; 14: 40-6.
51. Rovers JP, Saarnak AE, de Jode M, Sterenborg HJCM, Terpstra OT, Grahn MF. Biodistribution and Bioactivity of Tetrapegylated Metatetra(hydroxyphenyl)chlorine compared to native Metatetra(hydroxyphenyl)chlorin in a Rat Liver Tumor Model. Photochem Photobiol 2000; 71: 210-7.
52. Krueger T, Altermatt HJ, Mettler D, Scholl B, Magnusson L, Ris HB. Experimental Photodynamic Therapy for Malignant Pleural Mesothelioma With Pegylated mTHPC. Lasers Surg Med 2003; 32: 61-8.
53. Lottner C, Knuechel R, Bernhardt G, Brunner H. Distribution and subcellular localization of a water-soluble hematoporphyrinplatinum(II) complex in human bladder cancer cells. Cancer Lett 2004; 215: 167-77.
54. Lottner C, Bart K-C, Bernhardt G, Brunner H. Soluble Tetraarylporphyrin- Platinum Conjugates as Cytotoxic and Phototoxic Antitumor Agents. J Med Chem 2002; 45: 2079-89.
55. Sibrian-Vazquez M, Jensen TJ, Vicente MGH. Synthesis and cellular studies of PEG-functionalized meso-tetraphenylporphyrins. J Photochem Photobiol B 2007; 86: 9-21.
56. Mewis RE, Savoie H, Archibald SJ, Boyle RW. Synthesis and phototoxicity of polyethylene glycol (PEG) substituted metal-free and metallo-porphyrins: Effect of PEG chain length, coordinated metal, and axial ligand. Photodiagn Photodyn Ther 2009; 6: 200-6.
57. Arnold K, Pratsch L, Gawrisch K. Effect of poly(ethylene glycol) on phospholipid hydration and polarity of the external phase. Biochim Biophys Acta 1983; 728: 121-8.
58. Nawalany K, Kozik B, Kepczynski M, et al. Properties of Polyethylene Glycol Supported Tetraarylporphyrin in Aqueous Solution and Its Interaction with Liposomal Membranes. J Phys Chem B 2008; 112: 12231-9.
59. Tirosh O, Barenholz Y, Katzhendler J, Priev A. Hydration of Polyethylene Glycol-Grafted Liposomes. Biophys J 1998; 74: 1371-9.
60. Makky A, Michel JP, Ballut S, Kasselouri A, Maillard P, Rosilio V. Effect of Cholesterol and Sugar on the Penetration of Glycodendrimeric Phenylporphyrins into Biomimetic Models of Retinoblastoma Cells Membranes. Langmuir 2010; 26: 11145-56.
61. Parhamifar L, Larsen AK, Hunter AC, Andresen TL, Moghimi SM. Polycation cytotoxicity: a delicate matter for nucleic acid therapy-focus on polyethylenimine. Soft Mater 2010; 6: 4001-9.
62. Sikor M, Sabin J, Keyvanloo A, et al. Interaction of a Charged Polymer with Zwitterionic Lipid Vesicles. Langmuir 2010; 26: 4095-102.
63. Dai T, Tegos GP, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic Therapy for Methicillin-Resistant Staphylococcus aureus Infection in a Mouse Skin Abrasion Model. Lasers Surg Med 2010; 42: 38-44.
64. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: A new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004; 34: 426-38.
65. Huang L, Zhiyentayev T, Xuan Y, Azhibek D, Kharkwal GB, Hamblin MR. Photodynamic Inactivation of Bacteria Using Polyethylenimine- Chlorin(e6) Conjugates: Effect of Polymer Molecular Weight, Substitution Ratio of Chlorin(e6) and pH. Lasers Surg Med 2011; 43: 313-23.
66. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Veterinarni Medicina 2008; 53: 397-411.
67. Li F, Bae B-C, Na K. Acetylated Hyaluronic Acid/Photosensitizer Conjugate for the Preparation of Nanogels with Controllable Phototoxicity: Synthesis, Characterization, Autophotoquenching Properties, and in Witro Phototoxicity against HeLa Cells. Bioconjugate Chem 2010; 21: 1312-20.
68. Jin CS, Zheng G. Liposomal Nanostructures for Photosensitizer Delivery. Lasers Surg Med 2011; 43: 734-48.
69. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 1991; 88: 11460-4.
70. Ali MFM. Topical delivery and photodynamic evaluation of a multivesicular liposomal Rose Bengal. Lasers Med Sci 2011; 26: 267-75.
71. Mahjour M, Mauser B, Rashidbaigi Z, Fawzi MB. Effect of egg yolk lecithins and commercial soybean lecithins on in vitro skin permeation of drugs. J Control Release 1990; 14: 243-52.
72. Valjakka-Koskela R, Kirjavainen M, Monkkonen J, Urtti A, Kiesvaara J. Enhancement of percutaneous absorption of naproxen by phospholipids. Int J Pharm 1998; 175: 225-30.
73. Fang Y-P, Tsai Y-H, Wu P-Ch, Huang Y-B. Comparison of 5- aminolevulinic acid-encapsulated liposome versusethosome for skin delivery for photodynamic therapy. Int J Pharm 2008; 356: 144-52.
74. Zhang J, Deng L, Yao J, et al. Synthesis and photobiological study of a novel chlorin photosensitizer BCPD-18MA for photodynamic therapy. Bioorg Med Chem 2011; 19: 5520-8.
75. Guelluy PH, Fontaine-Aupart MP, Grammenos A, Lecart S, Pietted J, Hoebeke M. Optimizing photodynamic therapy by liposomal formulation of the photosensitizer pyropheophorbide-a methyl ester: In vitro and ex vivo comparative biophysical investigations in a colon carcinoma cell line. Photochem Photobiol Sci 2010; 9: 1252-60.
76. Xiao Z, Owen RJ, Liu W, Tulip J, Brown K, Woo T, Moore RB. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Photodiagn Photodyn Ther 2010; 7: 106-14.
77. Garrier J, Bezdetnaya L, Barlier C, Gräfe S, Guillemin F, D'Hallewin MA. Foslip®-based photodynamic therapy as a means to improve wound healing. Photodiagn Photodyn Ther 2011; doi:10.1016/j.pdpdt.2011.06.003.
78. Hu L, Huang B, Zuo M, Guo R, Wei H. Preparation of the phycoerythrin subunit liposome in a photodynamic experiment on liver cancer cells. Acta Pharmacol Sin 2008; 29: 1539-46.
79. Longo JPE, Leal SC, Simioni AR, et al. Photodynamic therapy disinfection of carious tissue mediated by aluminum-chloridephthalocyanine entrapped in cationic liposomes: an in vitro and clinical study. Lasers Med Sci 2011; DOI 10.1007/s10103-011- 0962-6.
80. Nawalany K, Rusin A, Kepczynski M, et al. Comparison of photodynamic efficacy of tetraarylporphyrin pegylated or encapsulated in liposomes: In vitro studies. J Photochem Photobiol B 2009; 97: 8-17.
81. Oleinick NL, Moris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how? Photochem Photobiol Sci 2002; 1: 1-21.
82. Morgan J, Oseroff AR. Mitochondia-based photodynamic anticancer therapy. Adv Drug Delivery Rev 2001; 49: 71-86.
83. Ichinose S, Usuda J, Hirata T, et al. Lysosomal cathepsin initiates apoptosis, which is regulated by photodamage to Bcl-2 at mitochondria in photodynamic therapy using a novel photosensitizer, ATX-s10 (Na). Int J Oncology 2006; 29: 349-55.
84. He P, Ahn JC, Shin JI, Chung PS. Photoactivation of 9- hydroxypheophorbide alpha triggers apoptosis through the reactive oxygen species-mediated mitochondrial pathway and endoplasmic reticulum stress in AMC-HN-3 laryngeal cancer cells. Int J Oncology 2010; 36: 801-8.
85. Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Phillips DR. Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem Photobiol 1991; 54: 725-32.
86. Nishiyama N, Nakagishi Y, Morimoto Y, et al. Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine. J Control Release 2009; 133: 245-251
87. Li P, Zhou G, Zhu X, Li G, Yanc P, Shena L, Xua Q, Hamblind MR. Photodynamic therapy with hyperbranched poly(ether-ester) chlorin(e6) nanoparticles on human tongue carcinoma CAL-27 cells. Photodiagn Photodyn Ther 2011; doi:10.1016/j.pdpdt.2011.08.006.
88. García-Díaz M, Nonell S, Villanueva A, et al. Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity? Acta Biochim Biophys 2011; 1808: 1063-107.